多囊卵巢综合征 中国就医指南

Polycystic Ovary Syndrome (PCOS) is a common, heterogeneous endocrine-metabolic disorder affecting individuals of reproductive age, characterized by chronic anovulation, hyperandrogenism (clinical or biochemical), and polycystic ovarian morphology on ultrasound—diagnosed using the Rotterdam criteria requiring at least two of these three features. PCOS is not merely a gynecologic condition but a systemic disorder with implications for metabolic health, cardiovascular risk, mental well-being, and long-term fertility. Its pathogenesis remains incompletely understood but involves a complex interplay of genetic susceptibility, neuroendocrine dysregulation (e.g., elevated luteinizing hormone [LH] pulse frequency, altered gonadotropin-releasing hormone [GnRH] secretion), insulin resistance, and adipose tissue dysfunction. Hyperinsulinemia exacerbates ovarian androgen production and impairs follicular development, while chronic low-grade inflammation and gut microbiota alterations are emerging as contributing factors. Epidemiologically, PCOS affects approximately 6–12% of women globally, though prevalence varies by diagnostic criteria and population—studies in China report rates of 5.6–8.7% among reproductive-aged women. Risk factors include family history (strong heritability), obesity (especially central adiposity), sedentary lifestyle, prenatal androgen exposure, and early menarche. Importantly, PCOS is underdiagnosed in many settings due to symptom variability and normalization of menstrual irregularities. Beyond reproductive concerns—such as oligomenorrhea, amenorrhea, infertility, and recurrent pregnancy loss—PCOS significantly impacts quality of life. Patients frequently experience anxiety, depression, body image distress, and reduced sexual satisfaction linked to hirsutism, acne, alopecia, and weight gain. Metabolic comorbidities—including prediabetes (30–40%), type 2 diabetes (up to 10% by age 40), dyslipidemia, non-alcoholic fatty liver disease (NAFLD), and obstructive sleep apnea—further diminish functional capacity and increase long-term morbidity. Cardiovascular risk markers (e.g., endothelial dysfunction, elevated C-reactive protein) are often present decades before clinical events. Early diagnosis and multidisciplinary management—integrating reproductive endocrinology, nutrition, behavioral health, and metabolic medicine—are essential to mitigate both immediate symptoms and lifelong health consequences.

# 多囊卵巢综合征（PCOS）治疗方案与费用明细（生殖医学科）

一、非手术/保守治疗方案

适用人群：初诊、轻中度高雄激素血症、有生育需求或代谢异常者。

• •生活方式干预（含营养师+运动处方）：3,200–5,800元/6个月（含体脂分析、胰岛素抵抗评估、随访6次）
• •一线药物治疗：

- 二甲双胍缓释片（改善IR）：98–260元/盒，联合用药时总药费约1,500–3,000元/年

• •促排卵治疗（克罗米芬/来曲唑）：单周期监测费（B超+性激素）1,800–2,600元；来曲唑药费260–420元/周期

二、微创介入治疗方案

适用人群：药物抵抗型、卵巢体积＞10mL、LH/FSH＞2且反复无排卵者。

• •腹腔镜下卵巢打孔术（LOD）：

- 手术费+麻醉+住院（3天）：12,800–18,500元（含术后3次排卵监测）

三、复杂/耐药/并发症方案

• •合并重度胰岛素抵抗（HOMA-IR≥4.5）：GLP-1受体激动剂（司美格鲁肽）医保外自费：2,100–3,600元/月×3–6月
• •合并不孕+输卵管因素：需衔接IVF助孕，基础周期费用32,000–45,000元

方案快速选择指南

✅ 预算＜5,000元/年：首选生活方式干预+来曲唑促排 ✅ 有生育急迫需求：直接启动促排卵监测或LOD（15,000元内闭环） ✅ 合并糖尿病/肥胖BMI≥30：必须联合二甲双胍+GLP-1管理，年投入约2.5–4万元